Question-and-Answer Session
Operator
[Operator Instructions] Your first question comes from the line of Joaquin (inaudible) from Nolan Berger Capital. Please proceed.
Joaquin - Nolan Berger Capital
Good morning guys.
Eric A. Rose - Chief Executive Officer and Chairman of the Board
Hi Joaquin, how are you?
Joaquin - Nolan Berger Capital
Great. Just a couple of questions; one, can you comment on the child that you treated with the ST-246 and how the results are there?
Eric A. Rose - Chief Executive Officer and Chairman of the Board
The child was discharged from the hospital and has done remarkably well. He is now free of orthopox virus infection, and a report of the child’s illness appeared in Morbidity & Mortality Weekly Report, which is the publication wing of the CDC. So, we are very pleased with his course.
Joaquin - Nolan Berger Capital
In the last call you mentioned that your current trials of ST-246 with the NIH would be finalized in September or over within September, is that still on track?
Eric A. Rose - Chief Executive Officer and Chairman of the Board
I think they will be finished some time in the fall. I can’t say specifically they will be fully complete in September.
Joaquin - Nolan Berger Capital
Let me ask you, if you can comment on this. Is there any reason why you would have to wait or someone would have to wait for FDA approval before they order your product?
Eric A. Rose - Chief Executive Officer and Chairman of the Board
Based on the ordering pattern for the other smallpox products that are now in the stockpile both the Acambis vaccine and the recently purchased MVA vaccine from Bavarian Nordic, neither of those is an FDA approved product. So, we do think that there is an opportunity for us to have a request for proposals for smallpox antiviral sale prior to FDA approval.
Joaquin - Nolan Berger Capital
Will the product be sold other than, say, to the US government; are there opportunities to sell it to other foreign countries or, say, the World Health Organization or the UN or whatever.
Eric A. Rose - Chief Executive Officer and Chairman of the Board
There certainly are opportunities to sell this to foreign governments and in addition to the opportunity to sell into the BioShield program in the United States, there are also the opportunity to sell to the Department of Defense, and to analogous to Tamiflu and other bird flu antivirals, there is a market for this type of drug for private industry to protect their workforce.
- To read the full transcript on Seeking Alpha, click here »
